The thought is triggered by a new report released this week, "Emerging Biopharmaceutical Companies: Ensuring a Favorable Environment for Continued Innovation."
When people think about America's biopharmaceutical research companies, they envision large, mature companies. They're partly correct.
The description also includes a very active and important group of emerging biopharmaceutical companies.
Despite their smaller size, emerging biopharmaceutical research companies represent an increasing proportion of private sector R&D investment and serve as "a 'deep bench' for future growth and innovation," according to research conducted by the Boston Consulting Group.
These companies are often the source of new medicines for diseases previously without treatments. They have consistently grown jobs - some experiencing 12-fold increases in job growth - significantly higher than the growth rate of jobs in the U.S. As they've grown, these companies have become a critical source of high-value, high-wage jobs with base salaries that, in some states, were more than twice the average wages of other sectors.
However, for all of their successes, these companies are vulnerable to an uncertain policy and regulatory environment - ever-changing new laws and regulations at the state and federal levels that undervalue medical advances. I urge you to read more about their future promise and the challenges they face here.
John Castellani John J. Castellani is past President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA). He is a passionate advocate for a strong, innovative and growing American biopharmaceutical research industry that plays a critical role in helping to improve the health of every American and patients the world-over. Mr. Castellani is also the former President and CEO of Business Roundtable, an association of chief executive officers of leading U.S. corporations with a combined workforce of nearly 12 million employees and $6 trillion in annual revenues.